ENV-501 vs Nezutatug

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: HER3 · full Non-Small Cell Lung Cancer pipeline

ENV-501

Developed by Hummingbird Bioscience

Phase 1/2 in Non-Small Cell Lung Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2027 · NCT06956690 (registry estimate)

No aligned efficacy figure on record for this race.

Nezutatug

Developed by Hummingbird Bioscience

Phase 1/2 in Non-Small Cell Lung Cancermonoclonal antibody
Weak signal

NCT05057013 · Phase 1/2 · active, not recruiting

The trial has no randomization, no blinding, and no control or comparator arm — it is a dose-escalation safety study designed to find a tolerable dose, not to test efficacy against a comparator. While outside reporting shows no dose-limiting toxicities were seen across six dose cohorts, this is a single-arm safety observation with no statistical comparison, so it cannot count as strong or even moderate clinical evidence of efficacy.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2027 · NCT05910827 (registry estimate)

Reported efficacy

Number of Participants Who Experienced Dose Limiting Toxicities (DLTs); Part A (From first dose onwards until completion of Cycle 1 (28 days)); Number of Participants Who Experienced DLTs; Part B Arm 1 (From first dose of combination therapy onwards until completion of Cycle 1 (28 days)); Number of adverse events (AEs) by arm considered to be at least possibly related to HMBD-001 (Part A and Part B Arm 1) (From the date of written informed consent until the end of the safety follow-up period (maximum [max] 42 weeks per participant)); Number of Grade 3, 4 and 5 AEs by arm considered to be at least possibly related to HMBD-001 (Part A and Part B Arm 1) (From the date of written informed consent until the end of the safety follow-up period (max 42 weeks per participant)); Overall response rate (ORR) within 6 cycles of HMBD-001 (Part B Arm 1) (From baseline radiological disease assessment until 28 days after last dose of HMBD-001 (max 36 weeks per participant)): HMBD-001 (NCT05057013), Part A dose escalation: cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs). (not_applicable)

Result source: NCT05057013

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointENV-501Nezutatug
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

ENV-501
—Not reported
Nezutatug
—Not reported

OS, median

ENV-501
—Not reported
Nezutatug
—Not reported

ORR

ENV-501
—Not reported
Nezutatug
—Not reported

Duration of response, median

ENV-501
—Not reported
Nezutatug
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ENV-501: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Nezutatug
HMBD-001 (NCT05057013), Part A dose escalation: cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs). NCT05057013 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ENV-501's landscape · Nezutatug's landscape